# Lactose intolerance and probiotics: from pathophysiological mechanisms to clinical applications

**Authors:** Tsachi Tsadok Perets, Rachel Gingold-Belfer, Ram Dickman

PMC · DOI: 10.1007/s10482-026-02278-x · Antonie Van Leeuwenhoek · 2026-03-17

## TL;DR

This paper reviews how probiotics may help manage lactose intolerance by improving digestion and reducing symptoms.

## Contribution

The paper provides a comprehensive review of probiotics as a novel treatment strategy for lactose intolerance.

## Key findings

- Probiotics may alleviate lactose intolerance symptoms by modulating colonic metabolism.
- Current management includes dietary restrictions and lactase formulations, but probiotics offer an alternative.
- Lactose intolerance affects up to 90% of adults in certain regions, with symptoms like bloating and diarrhea.

## Abstract

Lactose is a disaccharide found in dairy products, which provide energy and essential nutrients. Digestion of lactose relies on the intestinal enzyme lactase, or lactase-phlorizin hydrolase, located on the brush border of the small bowel mucosa. This enzyme splits lactose into two absorbable monosaccharides: glucose and galactose. When lactase activity is insufficient, undigested lactose proceeds to the colon where it is fermented by the gut flora, generating gas that trigger the uncomfortable symptoms associated with lactose intolerance. Lactase non-persistence is extremely common, affecting approximately 70% of the adult population world-wide. Prevalence varies markedly across geographic regions, typically ranging from 50 to 90% in African, Asian, and South American countries. The subjective diagnosis of lactose intolerance requires the occurrence of symptoms such as abdominal pain, bloating, flatulence and diarrhea following the ingestion of high lactose dairy products. An objective assessment of lactose intolerance may be achieved with a specific breath test that measures hydrogen emission in breath following the ingestion of lactose. Consequently, current international guidelines require concurrent report of typical symptoms and pathologic breath test results in order to diagnose lactose intolerance. Management of lactose intolerance often involves dietary restrictions and the prescription of formulations that contain lactase. However, one should recognize that avoiding dairy products can increase the risk of nutritional deficiencies. Therefore, ongoing research is focused on alternative strategies, notably utilizing gut microbiota in order to improve tolerance to lactose. This review aims to explore the evidence supporting the use of probiotics as a potential treatment strategy to alleviate the symptoms of lactose intolerance by modulating colonic metabolism and enhancing lactose digestion.

## Linked entities

- **Proteins:** lct.2.L (lactase, gene 2 L homeolog)
- **Chemicals:** lactose (PubChem CID 6134), glucose (PubChem CID 5793), galactose (PubChem CID 6036), hydrogen (PubChem CID 783)
- **Diseases:** lactose intolerance (MONDO:0100345)

## Full-text entities

- **Genes:** LCT (lactase) [NCBI Gene 3938] {aka LAC, LPH, LPH1}
- **Diseases:** Diarrhea (MESH:D003967), osteoporosis (MESH:D010024), infectious gastroenteritis (MESH:D005759), CLD (MESH:C562600), autosomal recessive disease (MESH:D030342), vertigo (MESH:D014717), vomiting (MESH:D014839), IBS (MESH:D043183), bone fracture (MESH:D050723), -Type Hypolactasia (MESH:D007787), cramping (MESH:D009120), celiac disease (MESH:D002446), inflammatory (MESH:D007249), nutrient deficiencies (MESH:D007153), memory impairment (MESH:D008569), headache (MESH:D006261), parasitic diseases (MESH:D010272), mouth ulcers (MESH:D019226), flatulence (MESH:D005414), nausea (MESH:D009325), abdominal pain (MESH:D015746), defective bone mineralization (MESH:D012080), gastrointestinal symptoms (MESH:D012817), malabsorption (MESH:D008286), malnutrition (MESH:D044342), lethargy (MESH:D053609), Crohn's disease (MESH:D003424), Giardia (MESH:D005873), muscle/joint pain (MESH:D063806), Rotavirus gastroenteritis (MESH:D012400), watery diarrhea (MESH:D003969), intestinal injury (MESH:D007410), constipation (MESH:D003248), bloating (MESH:C535647)
- **Chemicals:** monosaccharides (MESH:D009005), Prebiotics (MESH:D056692), vitamin D (MESH:D014807), CO2 (MESH:D002245), carbohydrate (MESH:D002241), galactans (MESH:D005685), oligosaccharides (MESH:D009844), vitamin B12 (MESH:D014805), choline (MESH:D002794), glucose (MESH:D005947), galactose (MESH:D005690), butyrate (MESH:D002087), acetate (MESH:D000085), phosphorus (MESH:D010758), Vitamin B6 (MESH:D025101), water (MESH:D014867), propionate (MESH:D011422), potassium (MESH:D011188), disaccharide (MESH:D004187), SCFA (MESH:D005232), riboflavin (MESH:D012256), BIO-25 (-), Lactose (MESH:D007785), H2S (MESH:D006862), CH4 (MESH:D008697), calcium (MESH:D002118), H2 (MESH:D006859), lactate (MESH:D019344), lactulose (MESH:D007792)
- **Species:** Bifidobacterium animalis subsp. lactis (subspecies) [taxon 302911], Bifidobacterium animalis (species) [taxon 28025], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Lacticaseibacillus rhamnosus HN001 (strain) [taxon 486408], Homo sapiens (human, species) [taxon 9606], Limosilactobacillus reuteri (species) [taxon 1598], Bifidobacterium longum (species) [taxon 216816], Lactobacillus acidophilus (species) [taxon 1579], Lactiplantibacillus plantarum (species) [taxon 1590], Aspergillus oryzae (species) [taxon 5062], Saccharomyces boulardii [taxon 252598], gut metagenome (species) [taxon 749906]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12995986/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12995986/full.md

---
Source: https://tomesphere.com/paper/PMC12995986